
PGxCare provides AI-powered pharmacogenetic analysis that personalizes drug selection, dosing, and identifies clinically relevant drug–drug interactions. The platform applies proprietary machine learning algorithms to real-world patient data and a comprehensive drug database to generate patient-specific recommendations. It operates as a B2B SaaS solution and integrates with clinical data systems such as InterSystems for workflow deployment. Core technologies include VectorSearch and GenAI for data retrieval and interpretation. PGxCare targets healthcare providers and institutions seeking pharmacogenomics-driven prescribing support at scale.

PGxCare provides AI-powered pharmacogenetic analysis that personalizes drug selection, dosing, and identifies clinically relevant drug–drug interactions. The platform applies proprietary machine learning algorithms to real-world patient data and a comprehensive drug database to generate patient-specific recommendations. It operates as a B2B SaaS solution and integrates with clinical data systems such as InterSystems for workflow deployment. Core technologies include VectorSearch and GenAI for data retrieval and interpretation. PGxCare targets healthcare providers and institutions seeking pharmacogenomics-driven prescribing support at scale.
What they do: AI-powered pharmacogenetics platform that personalizes drug selection and dosing
Customer type: B2B SaaS for healthcare providers and institutions
Founded: 2023
Funding: Seed round (Mar 19, 2024) led by ATEM Capital Fund LP
Headcount (approx.): 12 employees
Precision medicine / pharmacogenomics for medication decision support
2023
Biotechnology
1500000
Other disclosed investor: Roman Smolevskiy
“Lead investor in Seed round: ATEM Capital Fund LP; additional investor: Roman Smolevskiy”